For Immediate Release

2020.02.21

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
https://www.daiichisankyo.com

Daiichi Sankyo Appoints New Corporate Officers

TOKYO, Japan (February 21, 2020) – Daiichi Sankyo Company, Limited today announced the appointment of new corporate officers, CIO and CISO effective from April 1, 2020.

 

1. Changes to Corporate Officers

Name

Current Responsibilities

New Responsibilities

Toshiaki Tojo

Member of the Board
Senior Executive Officer
In charge of Vaccine Business
and Quality & Safety Management

Member of the Board

Masahiko Ohtsuki

Executive Officer
Vice President of Business Development & Licensing Dept.

Senior Executive Officer
Head of Digital Transformation Management Div.

Shoji Hirashima

Executive Officer
Head of Global Brand Strategy Div.

Senior Executive Officer
Head of Global Brand Strategy Div.

Hironobu Furuta

Corporate Officer

Head of Corporate Affairs Div.

Executive Officer
Head of Corporate Affairs Div.

Masayuki Yabuta

Corporate Officer
Head of Biologics Div.

Executive Officer
Head of Biologics Div.

Wataru Takasaki

Corporate Officer
Head of R&D Div. and Vice President of Oncology Function

Executive Officer
Head of R&D Div.

Shinichi Tobita

Corporate Officer
Vice President of Tokyo Branch,
Sales & Marketing Div.

Corporate Officer
Vice President of Marketing Management Dept., Sales & Marketing Div.

Hideyuki Hirano

Corporate Officer

Vice President of External Affairs Dept.

Corporate Officer

In charge of External Affairs

Yoshikazu Fukuchi

Corporate Officer

Head of Medical Affairs Div.

Corporate Officer

In charge of Medical Affairs

Seiichiro Kumakura

Corporate Officer
Vice President of Research Function, R&D Div.

Corporate Officer
Vice President of Translational Medicine Function, R&D Div.

Hironobu Saito

Corporate Officer
Vice President of Oncology Clinical Development Dept., Oncology Function, R&D Div.

Corporate Officer
Head of Medical Affairs Div.

Miyuki Arai

Head of Quality & Safety Management Div.

Head of Quality Assurance & Regulatory Affairs Div.

Toru Takahashi

Vice President of Modality Research Laboratories, Biologics Div.

Corporate Officer
Vice President of Research Function, R&D Div.

Hiroto Kashiwase

Head of Pharmaceutical Technology  Div.

Corporate Officer
Head of Pharmaceutical Technology  Div.

Naoto Tsukaguchi

Vice President of Legal Affairs Dept., Corporate Affairs Div.

Corporate Officer
Vice President of Legal Affairs Dept., Corporate Affairs Div.

Akio Sakurai

Vice President of Sales Planning Dept., Sales & Marketing Div.

Corporate Officer
Vice President of Sales Planning Dept., Sales & Marketing Div.

Toshinori Agatsuma

Vice President of Oncology Research Laboratories I, Oncology Function, R&D Div.

Corporate Officer
Vice President of Oncology Research Laboratories I, Research Function, R&D Div.

â—‡Ryoji Nagasaka (current Executive Officer) will be appointed full-time Corporate Advisor as of April 1st, 2020.

 

2. Appointment of CIO and CISO

Chief Information Officer (CIO)

Masahiko Ohtsuki

Chief Information Security Officer (CISO)

Hironobu Furuta

  

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.